Journal
EUROPEAN JOURNAL OF HAEMATOLOGY
Volume 90, Issue 5, Pages 404-412Publisher
WILEY
DOI: 10.1111/ejh.12097
Keywords
acute lymphoblastic leukemia; adults; adolescents; children; minimal residual disease; pediatric protocol
Categories
Funding
- Danish Cancer Society
- Danish Childhood Cancer Foundation
- Herlev University Hospital Research Council
Ask authors/readers for more resources
Background The prognosis of acute lymphoblastic leukemia is poorer in adults than in children. Studies have indicated that young adults benefit from pediatric treatment, although no upper age limit has been defined. Design and methods We analyzed 749 patients aged 145yr treated by the NOPHO ALL-2008 protocol. Minimal residual disease (MRD) on days 29 and 79, immunophenotype, white blood cell count (WBC), and cytogenetics were used to stratify patients to standard-, intermediate-, or high-risk treatment with or without hematopoietic stem cell transplantation. Results Adults aged 1845 had significantly lower WBCs at diagnosis compared with children aged 19 and 1017yr, but significantly more adults were stratified to high-risk chemotherapy (8%, 14%, 17%; P<0.0001) or high-risk chemotherapy with transplantation (4%, 13%, 19%; P<0.0001). This age-dependent skewing of risk grouping reflected more T-ALL (11%, 27%, 33%, P<0.0001), poorer MRD response day 29 (MRD <0.1%: 75%, 61%, 52%; P<0.0001), and more MLL gene rearrangements (3%, 3%, 10%; P=0.005) in older patients. Conclusions Even if identical diagnostics, treatment, and risk stratification are implemented, more adults will be stratified to high-risk therapy, which should be considered when comparing pediatric and adult outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available